Nogo-A Antibody

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: WB, IP
Reactivity: H M R
Sensitivity: Endogenous
MW (kDa): 180
Source: Rabbit
UniProt ID: #Q9NQC3
Entrez-Gene Id: 57142

Product Usage Information

Application
Western Blotting
Immunoprecipitation

Dilution
1:1000
1:50

Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity
Nogo-A Antibody recognizes endogenous levels of total Nogo-A protein. Based on sequence homology, this antibody is not expected to recognize Nogo-B or Nogo-C.

Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly220 of human Nogo-A protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background
Neurite outgrowth inhibition protein (Nogo, RTN4) is a reticulon family protein that was identified as an axonal growth inhibitor of the central nervous system (CNS). Nogo occurs as three major isoforms (Nogo-A, Nogo-B, and Nogo-C) that share a common carboxy terminus of 188 amino acids. Nogo-A is transmembrane protein enriched in the endoplasmic reticulum and expressed at high levels in the CNS, and more weakly in skeletal and heart muscle (1-3). Expression of Nogo-A decreases with increasing age during brain development. In the adult CNS, negative regulation of neuronal growth leads to stabilization of the CNS wiring at the expense of extensive plastic rearrangements. Nogo-A mediates inhibition of neurite growth together with the nogo receptor 1 (NgR1), the p75 neurotrophin receptor p75NTR, and the transmembrane LINGO1 protein. This Nogo receptor signaling complex activates the RhoA/ROCK pathway, which collapses neuronal growth cones and inhibits axonal growth in the CNS following traumatic brain injury. Research studies suggest that inhibition of Nogo A may be beneficial to patients with traumatic brain injury. Nogo-B and Nogo-C inhibit BACE1 activity and amyloid precursor protein processing, suggesting a role in cell survival (4).

Background References

Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key
WB: Western Blotting
IP: Immunoprecipitation

Cross-Reactivity Key

Trademarks and Patents
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in...
writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.